Fosaprepitant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fosaprepitant
Skeletal formula of fosaprepitant
Space-filling model of the fosaprepitant molecule
Systematic (IUPAC) name
[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
Clinical data
AHFS/Drugs.com Multum Consumer Information
MedlinePlus a604003
Licence data EMA:Link, US FDA:link
Pregnancy
category
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration
Intravenous
Pharmacokinetic data
Bioavailability n/a
Protein binding >95% (aprepitant)
Metabolism To aprepitant
Biological half-life 9 to 13 hours (aprepitant)
Identifiers
CAS Registry Number 172673-20-0 YesY
265121-04-8 (dimeglumine)
ATC code A04AD12
PubChem CID: 219090
IUPHAR/BPS 7623
DrugBank DB06717 N
UNII 6L8OF9XRDC N
KEGG D06597 N
ChEMBL CHEMBL1199324 N
Chemical data
Formula C23H22F7N4O6P
Molecular mass 614.406 g/mol
 N (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]

See also[edit]

References[edit]